Correction: Overexpression of Wildtype EGFR is Tumorigenic and Denotes a Therapeutic Target in Non-Small Cell Lung Cancer

Naiqing Xu,Wenfeng Fang,Libing Mu,Yanna Tang,Lei Gao,Shengxiang Ren,Dengfeng Cao,Lei Zhou,Aiqun Zhang,Deruo Liu,Caicun Zhou,Kwok-Kin Wong,Lei Yu,Li Zhang,Chaozhao Liang

DOI: https://doi.org/10.18632/oncotarget.26254

2018-01-01

Oncotarget

Abstract:[This corrects the article DOI: 10.18632/oncotarget.6461.].

What problem does this paper attempt to address?

Overexpression of wildtype EGFR is tumorigenic and denotes a therapeutic target in non-small cell lung cancer.

Naiqing Xu,Wenfeng Fang,Libing Mu,Yanna Tang,Lei Gao,Shengxiang Ren,Dengfeng Cao,Lixin Zhou,Aiqun Zhang,Deruo Liu,Caicun Zhou,Kwok-Kin Wong,Lei Yu,Li Zhang,Liang Chen

DOI: https://doi.org/10.18632/oncotarget.6461

2016-01-01

Oncotarget

Abstract:Current guidelines for lung cancer treatment with EGFR tyrosine kinase inhibitors (TKI) include only patients with mutated EGFR, although some patients with wildtype EGFR (wt-EGFR) have exhibited positive responses to this therapy as well. Biomarkers predicting the benefit from EGFR-TKIs treatment remain to be determined for patients with wild-type EGFR.Here, we report that wt-EGFR overexpression transformed cells in vitro and induced tumorigenesis in vivo in transgenic mouse models. Wt-EGFR driven lung cancer was hypersensitive to TKI treatment in mouse model. Lung cancer patients with high-expression of wt-EGFR showed longer Overall Survival in comparison to low-expression patients after TKI treatment. Our data therefore suggest that treatment with EGFR inhibitors should be extended to include not only patients with mutated EGFR but also a subset of patients with overexpression of wt-EGFR.
Overcoming erlotinib resistance in EGFR mutation-positive lung adenocarcinomas through repression of phosphoglycerate dehydrogenase: Erratum

Jiang-Kai Dong,Hui-Min Lei,Qian Liang,Ya-Bin Tang,Ye Zhou,Yang Wang,Shengzhe Zhang,Wen-Bin Li,Yunguang Tong,Guanglei Zhuang,Liang Zhang,Hong-Zhuan Chen,Liang Zhu,Ying Shen

DOI: https://doi.org/10.7150/thno.58558

IF: 11.6

2021-01-01

Theranostics

Abstract:[This corrects the article DOI: 10.7150/thno.23177.].

medicine, research & experimental
Correction: Tumor Driven by Gain-of-function HER2 H878Y Mutant is Highly Sensitive to HER2 Inhibitor.

Zexi Hu,Yong Hu,Xicheng Liu,Rongwen Xi,Aiqun Zhang,Deruo Liu,Qiang Xie,Liang Chen

DOI: https://doi.org/10.18632/oncotarget.26252

2018-01-01

Oncotarget

Abstract:[This corrects the article DOI: 10.18632/oncotarget.5221.].
Corrigendum: EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy As First-Line Therapy for Non-Small Cell Lung Cancer Patients with the L858R Point Mutation.

Jianlin Xu,Haitang Yang,Bo Jin,Yuqing Lou,Yanwei Zhang,Xueyan Zhang,Hua Zhong,Huiming Wang,Dan Wu,Baohui Han

DOI: https://doi.org/10.1038/srep38270

IF: 4.6

2016-01-01

Scientific Reports

Abstract:Scientific Reports 6: Article number: 36371; published online: 04 November 2016; updated: 01 December 2016
Correction: Loss of EGFR Signaling-Regulated Mir-203 Promotes Prostate Cancer Bone Metastasis and Tyrosine Kinase Inhibitors Resistance

Man Kit Siu,Wassim Abou-Kheir,Juan,Yung-Chieh Chang,Ben Barrett,Florent Suau,Órla Casey,Wei-Yu Chen,Lei Fang,Paul G. Hynes,Yao-Yu Hsieh,Yen-Nien Liu,Jiaoti Huang,Kathleen Kelly

DOI: https://doi.org/10.18632/oncotarget.26020

2018-01-01

Oncotarget

Abstract:[This corrects the article DOI: 10.18632/oncotarget.1994.].
Correction: Clinical Significance and Effect of AEG-1 on the Proliferation, Invasion, and Migration of NSCLC: a Study Based on Immunohistochemistry, TCGA, Bioinformatics, in Vitro and in Vivo Verification.

Yu Zhang,Zu-Yun Li,Xin-Xi Hou,Xiao Wang,Yi-Huan Luo,Yan-Ping Ying,Gang Chen

DOI: https://doi.org/10.18632/oncotarget.28212

2022-01-01

Oncotarget

Abstract:[This corrects the article DOI: 10.18632/oncotarget.14972.].
Author Correction: NRF2-GPX4/SOD2 axis imparts resistance to EGFR-tyrosine kinase inhibitors in non-small-cell lung cancer cells

Chun-shuang Ma,Qian-ming Lv,Ke-ren Zhang,Ya-bin Tang,Yu-fei Zhang,Ying Shen,Hui-min Lei,Liang Zhu

DOI: https://doi.org/10.1038/s41401-023-01131-5

IF: 7.169

2023-08-02

Acta Pharmacologica Sinica

Abstract:Acta Pharmacologica Sinica, Published online: 01 August 2023; doi:10.1038/s41401-023-01131-5 Author Correction: NRF2-GPX4/SOD2 axis imparts resistance to EGFR-tyrosine kinase inhibitors in non-small-cell lung cancer cells

pharmacology & pharmacy,chemistry, multidisciplinary
Author Correction: Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer

Jacqulyne P. Robichaux,Yasir Y. Elamin,Zhi Tan,Brett W. Carter,Shuxing Zhang,Shengwu Liu,Shuai Li,Ting Chen,Alissa Poteete,Adriana Estrada-Bernal,Anh T. Le,Anna Truini,Monique B. Nilsson,Huiying Sun,Emily Roarty,Sarah B. Goldberg,Julie R. Brahmer,Mehmet Altan,Charles Lu,Vassiliki Papadimitrakopoulou,Katerina Politi,Robert C. Doebele,Kwok-Kin Wong,John V. Heymach

DOI: https://doi.org/10.1038/s41591-024-03178-1

IF: 82.9

2024-08-22

Nature Medicine

Abstract:Nature Medicine, Published online: 20 August 2024; doi:10.1038/s41591-024-03178-1 Author Correction: Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer

biochemistry & molecular biology,cell biology,medicine, research & experimental
Author Correction: Exosome-delivered EGFR regulates liver microenvironment to promote gastric cancer liver metastasis

Haiyang Zhang,Ting Deng,Rui Liu,Ming Bai,Likun Zhou,Xia Wang,Shuang Li,Xinyi Wang,Haiou Yang,Jialu Li,Tao Ning,Dingzhi Huang,Hongli Li,Le Zhang,Guoguang Ying,Yi Ba

DOI: https://doi.org/10.1038/s41467-023-37320-3

IF: 16.6

2023-03-28

Nature Communications

Abstract:Nature Communications, Published online: 27 March 2023; doi:10.1038/s41467-023-37320-3 Author Correction: Exosome-delivered EGFR regulates liver microenvironment to promote gastric cancer liver metastasis

multidisciplinary sciences
[Corrigendum] Identification of Lncrna EGOT As a Tumor Suppressor in Renal Cell Carcinoma

Lu Jin,Jing Quan,Xiang Pan,Tao He,Jia Hu,Yifan Li,Yaoting Gui,Shangqi Yang,Xiangming Mao,Yun Chen,Yongqing Lai

DOI: https://doi.org/10.3892/mmr.2024.13194

IF: 3.423

2024-01-01

Molecular Medicine Reports

Abstract:Subsequently to the publication of the above paper, an interested reader drew to the authors' attention that, concerrning the Transwell cell migration and invasion assay data shown in Fig. 6A and B for the 786‑O cell line on p. 7206, the pcDNA3.1‑EGOT 'Migration' and 'Invasion' (a‑1 and b‑1) data panels appeared to contain overlapping sections of data, such that they were potentially derived from the same original source, where these panels were intended to show the results from differently performed experiments. The authors have re‑examined their original data, and realize that the 'Invasion' (b‑1) panel in Fig. 6B was inadvertently chosen incorrectly. The revised version of Fig. 6, now featuring the correct data for the 'Invasion' experiment (B1 in the replacement figure) in Fig. 6B, is shown on the next page. Note that this error did not adversely affect either the results or the overall conclusions reported in this study. All the authors agree with the publication of this corrigendum, and are grateful to the Editor of Molecular Medicine Reports for allowing them the opportunity to publish this. They also wish to apologize to the readership of the Journal for any inconvenience caused.[Molecular Medicine Reports 16: 7072‑7079, 2017; DOI: 10.3892/mmr.2017.7470].
Myeloid cell-derived LL-37 promotes lung cancer growth by activating Wnt/β-catenin signaling: Erratum

Ping Ji,Yongxin Zhou,Yibao Yang,Junlu Wu,Hao Zhou,Wenqiang Quan,Junjun Sun,Yiwen Yao,Anquan Shang,Chenzheng Gu,Bingjie Zeng,Jenni Firrman,Weidong Xiao,Robert Bals,Zujun Sun,Dong Li

DOI: https://doi.org/10.7150/thno.82877

IF: 11.6

2023-01-01

Theranostics

Abstract:[This corrects the article DOI: 10.7150/thno.30726.].

medicine, research & experimental
Correction To: Targeting the Epidermal Growth Factor Receptor in Non-Small Cell Lung Cancer Cells: the Effect of Combining RNA Interference with Tyrosine Kinase Inhibitors or Cetuximab

Gang Chen,Peter Kronenberger,Erik Teugels,Ijeoma Adaku Umelo,Jacques De Grève

DOI: https://doi.org/10.1186/s12916-020-1501-8

IF: 9.3

2020-01-01

BMC Medicine

Abstract:Following publication of the original article [1], the authors reported that there was an error in Figure 9, which contained a misplaced picture. The authors confirm that all of the published results and conclusions of the paper remain unchanged, as well as the figure legends. The authors apologize for any confusion caused. The corrected Figure 9 is shown as follows:
Corrigendum: Targeting HER3 to overcome RGFR TKI resistance in NSCLC

Qiuqiang Chen,Gang Jia,Xilin Zhang,Wenxue Ma

DOI: https://doi.org/10.3389/fimmu.2024.1376045

IF: 7.3

2024-01-31

Frontiers in Immunology

Abstract:[This corrects the article DOI: 10.3389/fimmu.2023.1332057.].

immunology
[Corrigendum] microRNA‐181a‐5p functions as an oncogene in renal cell carcinoma

Yulin Lai,Liwen Zhao,Jia Hu,Jing Quan,Peijie Chen,Jinling Xu,Xin Guan,Yongqing Lai,Liangchao Ni

DOI: https://doi.org/10.3892/mmr.2024.13182

IF: 3.423

2024-02-16

Molecular Medicine Reports

Abstract:Following the publication of the above article and a corrigendum in 2018 that corrected details of the correspondence information for authors, errors made in Fig. 5 and the funding details (doi: 10.3892/mmr.2018.9117), an interested reader drew to the authors' attention that, in Fig. 6 on p. 8515 showing the results of cell migration and invasion assay experiments, a pair of data panels were overlapping, such that data which were intended to show the results from differently performed experiments appeared to have been derived from the same original source. After having consulted their original data, the authors have realized that Fig. 6 was assembled incorrectly, The revised version of Fig. 6, now showing the correct data for the 'ACHN/migratory/NC' experiment, is shown on the next page. Note that all the authors approve of the publication of this corrigendum, and the authors are grateful to the Editor of Molecular Medicine Reports for granting them the opportunity to publish this. The authors regret their oversight in allowing this error to be included in the paper, and also apologize to the readership for any inconvenience caused. [Molecular Medicine Reports 17: 8510‐8517, 2018; DOI: 10.3892/mmr.2018.8899]

oncology,medicine, research & experimental
Erratum: Dual inhibition of PFKFB3 and VEGF normalizes tumor vasculature, reduces lactate production, and improves chemotherapy in glioblastoma: insights from protein expression profiling and MRI: Erratum

Junfeng Zhang,Wei Xue,Kai Xu,Liang Yi,Yu Guo,Tian Xie,Haipeng Tong,Bo Zhou,Shunan Wang,Qing Li,Heng Liu,Xiao Chen,Jingqin Fang,Weiguo Zhang

DOI: https://doi.org/10.7150/thno.92042

IF: 11.6

2023-11-17

Theranostics

Abstract:[This corrects the article DOI: 10.7150/thno.44427.].
Targeting Epstein-Barr virus oncoprotein LMP1-mediated high oxidative stress suppresses EBV lytic reactivation and sensitizes tumors to radiation therapy: Erratum

Jianmin Hu,Yueshuo Li,Hongde Li,Feng Shi,Longlong Xie,Lin Zhao,Min Tang,Xiangjian Luo,Weihua Jia,Jia Fan,Jian Zhou,Qiang Gao,Shuangjian Qiu,Weizhong Wu,Xin Zhang,Weihua Liao,Ann M. Bode,Ya Cao

DOI: https://doi.org/10.7150/thno.73630

IF: 11.6

2022-01-01

Theranostics

Abstract:[This corrects the article DOI: 10.7150/thno.46006.].

medicine, research & experimental
Erratum: ITGA2 Overexpression Promotes Esophageal Squamous Cell Carcinoma Aggression via FAK/AKT Signaling Pathway [Corrigendum]

DOI: https://doi.org/10.2147/OTT.S390829

2022-09-27

Abstract:[This corrects the article DOI: 10.2147/OTT.S302028.].
Erratum: Exogenous glutathione contributes to cisplatin resistance in lung cancer A549 cells.

Dong Lan,Li Wang,Rongquan He,Jie Ma,Yehong Bin,Xiaojv Chi,Gang Chen,Zhengwen Cai

2018-01-01

American journal of translational research

Abstract:[This corrects the article on p. 1295 in vol. 10, PMID: 29887946.].
Erratum to upregulation of long noncoding RNA RAB11B-AS1 promotes tumor metastasis and predicts poor prognosis in lung cancer

Tiegang Li,Di Wu,Qun Liu,Dedong Wang,Jinbin Chen,Hongjun Zhao,Lan Zhang,Chenli Xie,Wei Zhu,Zhixu Chen,Yifeng Zhou,Soham Datta,Fuman Qiu,Lei Yang,Jiachun Lu

DOI: https://doi.org/10.21037/atm-2020-41

IF: 3.616

2020-11-01

Annals of Translational Medicine

Abstract:[This corrects the article DOI: 10.21037/atm.2020.04.52.].

oncology,medicine, research & experimental
Correction: A Tissue Factor-Cascade-targeted Strategy to Tumor Vasculature: a Combination of EGFP-EGF1 Conjugation Nanoparticles with Photodynamic Therapy

Wei Shi,Yanxue Yin,Yao Wang,Bo Zhang,Pei Tan,Ting Jiang,Heng Mei,Jun Deng,Huafang Wang,Tao Guo,Zhiqing Pang,Yu Hu

DOI: https://doi.org/10.18632/oncotarget.25079

2018-01-01

Oncotarget

Abstract:[This corrects the article DOI: 10.18632/oncotarget.12922.].

Correction: Overexpression of Wildtype EGFR is Tumorigenic and Denotes a Therapeutic Target in Non-Small Cell Lung Cancer

Overexpression of wildtype EGFR is tumorigenic and denotes a therapeutic target in non-small cell lung cancer.

Overcoming erlotinib resistance in EGFR mutation-positive lung adenocarcinomas through repression of phosphoglycerate dehydrogenase: Erratum

Correction: Tumor Driven by Gain-of-function HER2 H878Y Mutant is Highly Sensitive to HER2 Inhibitor.

Corrigendum: EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy As First-Line Therapy for Non-Small Cell Lung Cancer Patients with the L858R Point Mutation.

Correction: Loss of EGFR Signaling-Regulated Mir-203 Promotes Prostate Cancer Bone Metastasis and Tyrosine Kinase Inhibitors Resistance

Correction: Clinical Significance and Effect of AEG-1 on the Proliferation, Invasion, and Migration of NSCLC: a Study Based on Immunohistochemistry, TCGA, Bioinformatics, in Vitro and in Vivo Verification.

Author Correction: NRF2-GPX4/SOD2 axis imparts resistance to EGFR-tyrosine kinase inhibitors in non-small-cell lung cancer cells

Author Correction: Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer

Author Correction: Exosome-delivered EGFR regulates liver microenvironment to promote gastric cancer liver metastasis

[Corrigendum] Identification of Lncrna EGOT As a Tumor Suppressor in Renal Cell Carcinoma

Myeloid cell-derived LL-37 promotes lung cancer growth by activating Wnt/β-catenin signaling: Erratum

Correction To: Targeting the Epidermal Growth Factor Receptor in Non-Small Cell Lung Cancer Cells: the Effect of Combining RNA Interference with Tyrosine Kinase Inhibitors or Cetuximab

Corrigendum: Targeting HER3 to overcome RGFR TKI resistance in NSCLC

[Corrigendum] microRNA‐181a‐5p functions as an oncogene in renal cell carcinoma

Erratum: Dual inhibition of PFKFB3 and VEGF normalizes tumor vasculature, reduces lactate production, and improves chemotherapy in glioblastoma: insights from protein expression profiling and MRI: Erratum

Targeting Epstein-Barr virus oncoprotein LMP1-mediated high oxidative stress suppresses EBV lytic reactivation and sensitizes tumors to radiation therapy: Erratum

Erratum: ITGA2 Overexpression Promotes Esophageal Squamous Cell Carcinoma Aggression via FAK/AKT Signaling Pathway [Corrigendum]

Erratum: Exogenous glutathione contributes to cisplatin resistance in lung cancer A549 cells.

Erratum to upregulation of long noncoding RNA RAB11B-AS1 promotes tumor metastasis and predicts poor prognosis in lung cancer

Correction: A Tissue Factor-Cascade-targeted Strategy to Tumor Vasculature: a Combination of EGFP-EGF1 Conjugation Nanoparticles with Photodynamic Therapy